Loading stock data…
ZBIO
$19.36+0.04 (+0.21%)
Market ClosedLast close May 1
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ZBIO in the Healthcare sector is trading at $19.36. The stock is currently 57% below its 52-week high of $44.60, remaining 20.0% below its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why ZBIO maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.36
Potential Upside
5%
Whystock Fair Value$20.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Mean target$42.00+116.9%
Range$21.00 – $55.00
Fundamentals
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-156.00%
Volume
Today's trading volume
786,596
Recent News
Insiders Are Scooping Up These 2 ‘Strong Buy’ Stocks
Every investor is looking for an edge, yet the market offers no shortage of strategies, each promising to be the one that finally cracks the code. Some rely on charts, others follow macro trends, while many stick with dividends or lean on analyst opinions. The challenge isn’t finding ideas – it’s figuring out which ones actually hold up when it matters. One approach that has consistently earned its place is tracking insider activity. Executives, board members, and senior leaders aren’t just obse
Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk
Zenas BioPharma (NasdaqGS:ZBIO) has completed a follow on equity offering and a convertible senior notes offering. The combined transactions provide capital for the planned U.S. commercial launch of obexelimab. Funds are also earmarked for further clinical development across the company’s pipeline. Zenas BioPharma focuses on developing and commercializing therapies such as obexelimab, with an eye on U.S. market entry. For investors, the recent capital raise is tied to bringing this asset to...
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Friday afternoon, with the NYSE Health Care Index down 0.8% and the
Sector Update: Health Care Stocks Retreat Friday Afternoon
Health care stocks declined Friday afternoon, with the NYSE Health Care Index down 0.6% and the Stat
Wall Street Set to Open Lower in Friday Trading; Investors Not Assuaged by US Deadline Extension for Iran to Open Strait of Hormuz
US stocks look set to open lower in Friday's trading session, as President Donald Trump's deadline e